Zachary Berman

Zachary Berman and Kirema Garcia-Reyes, interventional radiologists, share their expertise on Y-90 dosimetry, stressing that it's not a one-size-fits-all approach. They discuss factors influencing dosing, such as tumor size and underlying liver function. The guests reflect on gaps in training and the evolution of dosimetry education in interventional radiology. Real-life case examples illustrate the complexities of individualized treatment plans. They also critique planning software and underscore the importance of empirical approaches to achieve optimal dosages.

Dr. Zachary Berman, a hepatobiliary interventional oncologist and Associate Clinical Professor of Radiology at UC San Diego, shares expertise on microwave ablation for hepatocellular carcinoma (HCC). He emphasizes a multidisciplinary approach, discussing the roles of tumor boards and collaborative care. Berman elaborates on pre-procedure imaging, the importance of ultrasound skills, and navigating complex cases. The conversation also touches on the integration of immunotherapy and advanced imaging techniques to enhance ablation outcomes.

Dr. Zachary Berman, an interventional radiologist at UC San Diego, offers insights into pressure-enabled drug delivery for liver cancers. He explains how manipulating blood flow in tumors can optimize drug delivery, showcasing the innovative TriNav catheter's design. The discussion delves into real-world applications, including case studies of complex tumors like neuroendocrine lesions and segmental HCC. Additionally, they cover advancements in pressure-directed embolotherapy and the exciting potential future developments in enhancing treatment effectiveness.

In this engaging discussion, medical oncologists Adam Burgoyne and Lingling Du, alongside interventional radiologists Kirema Garcia-Reyes and Zachary Berman, tackle the complexities of hepatocellular carcinoma (HCC) treatment. They explore the 'grey zone' in treatment goals, emphasizing the importance of performance status and comprehensive liver function assessments. The guests share insights on navigating advanced liver disease, the role of immunotherapy, and the critical need for multidisciplinary collaboration to optimize patient outcomes.

Join experts Jonathan Mizrah, a medical oncologist at Ochsner Health specializing in HCC treatment, Lingling Du, who focuses on HCC trials, Adam Burgoyne from UCSD discussing immunotherapy communication, and interventional radiologist Zachary Berman on an insightful exploration of advanced liver cancer treatments. They discuss the promising role of combination therapies, particularly TACE with immunotherapy, and dive into groundbreaking clinical trial results. Simplifying complex mechanisms, they emphasize the importance of personalized treatment strategies and ongoing patient care.